ES2166098T3 - Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos. - Google Patents

Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos.

Info

Publication number
ES2166098T3
ES2166098T3 ES97936682T ES97936682T ES2166098T3 ES 2166098 T3 ES2166098 T3 ES 2166098T3 ES 97936682 T ES97936682 T ES 97936682T ES 97936682 T ES97936682 T ES 97936682T ES 2166098 T3 ES2166098 T3 ES 2166098T3
Authority
ES
Spain
Prior art keywords
group
groups
carbon atoms
oxo
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97936682T
Other languages
English (en)
Inventor
Gerard Moinet
Lilian Doare
Micheline Kergoat
Philippe Maizeray
Didier Mesangeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2166098T3 publication Critical patent/ES2166098T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: COMO PRINCIPIO ACTIVO, UN COMPUESTO DE FORMULA (I) EN LA QUE LOS GRUPOS A Y B SE ELIGEN INDEPENDIENTEMENTE EL UNO DEL OTRO ENTRE: UN GRUPO ARILO MONO-, BI- O TRICICLO QUE TIENE ENTRE 6 Y 14 ATOMOS DE CARBONO; UN GRUPO HETEROAROMATICO ELEGIDO ENTRE LOS GRUPOS PIRIDILO, PIRIMIDILO, PIRROLILO, FURILO Y TIENILO; UN GRUPO ALQUILO QUE TIENE ENTRE 1 Y 14 ATOMOS DE CARBONO; UN GRUPO CICLOALQUILO QUE TIENE ENTRE 5 Y 8 ATOMOS DE CARBONO; UN GRUPO HETEROCICLICO SATURADO ELEGIDO ENTRE LOS GRUPOS TETRAHIDROFURILO, TETRAHIDROPIRRANILO, PIPERIDINILO Y PIRROLODINILO; SU SOLVATO O UNA SAL DE ESTE ACIDO CON UNA BASE FARMACEUTICAMENTE ACEPTABLE.
ES97936682T 1996-08-16 1997-08-05 Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos. Expired - Lifetime ES2166098T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9610254A FR2752422B1 (fr) 1996-08-16 1996-08-16 Composition pharmaceutique contenant des acides 4-oxo-butanoiques

Publications (1)

Publication Number Publication Date
ES2166098T3 true ES2166098T3 (es) 2002-04-01

Family

ID=9495089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97936682T Expired - Lifetime ES2166098T3 (es) 1996-08-16 1997-08-05 Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos.

Country Status (30)

Country Link
US (1) US6143787A (es)
EP (1) EP0925273B1 (es)
JP (1) JP3105545B2 (es)
KR (1) KR100488430B1 (es)
CN (1) CN1082370C (es)
AR (1) AR009251A1 (es)
AT (1) ATE208364T1 (es)
AU (1) AU725440B2 (es)
BR (1) BR9711315A (es)
CA (1) CA2263348C (es)
CY (1) CY2298B1 (es)
CZ (1) CZ294165B6 (es)
DE (1) DE69708130T2 (es)
DK (1) DK0925273T3 (es)
ES (1) ES2166098T3 (es)
FR (1) FR2752422B1 (es)
HK (1) HK1021728A1 (es)
HU (1) HUP0004223A3 (es)
ID (1) ID17875A (es)
NO (1) NO312290B1 (es)
PL (1) PL187371B1 (es)
PT (1) PT925273E (es)
RU (1) RU2175966C2 (es)
SI (1) SI0925273T1 (es)
SK (1) SK283055B6 (es)
TR (1) TR199900329T2 (es)
TW (1) TW438764B (es)
UA (1) UA57031C2 (es)
WO (1) WO1998007681A1 (es)
ZA (1) ZA977327B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04318852A (ja) * 1991-04-18 1992-11-10 Fujitsu Ltd レジスト・パターン形成方法
NZ530051A (en) 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
FR2832633B1 (fr) * 2001-11-28 2004-09-24 Lipha Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
FR2832925B1 (fr) * 2001-12-03 2006-07-14 Lipha Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
FR2834214B1 (fr) * 2001-12-28 2004-09-24 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
FR2834640B1 (fr) * 2002-01-11 2004-09-24 Lipha Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete
AU2003286728A1 (en) * 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ATE468114T1 (de) * 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
FR2849599B1 (fr) * 2003-01-07 2006-12-29 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
WO2004091486A2 (en) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20100273872A1 (en) 2007-12-03 2010-10-28 Valerie Autier Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250517A (en) * 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
CA1329680C (en) * 1987-11-23 1994-05-17 Harold Norris Weller, Iii N-heterocyclic alcohol derivatives
US5055466A (en) * 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents

Also Published As

Publication number Publication date
DK0925273T3 (da) 2002-02-18
AU3942297A (en) 1998-03-06
CA2263348C (en) 2008-05-13
PT925273E (pt) 2002-04-29
ID17875A (id) 1998-02-05
CA2263348A1 (fr) 1998-02-26
NO990707D0 (no) 1999-02-15
DE69708130D1 (de) 2001-12-13
HUP0004223A2 (hu) 2001-04-28
FR2752422A1 (fr) 1998-02-20
DE69708130T2 (de) 2002-06-20
UA57031C2 (uk) 2003-06-16
JP3105545B2 (ja) 2000-11-06
SK283055B6 (sk) 2003-02-04
HK1021728A1 (en) 2000-06-30
HUP0004223A3 (en) 2001-12-28
KR100488430B1 (ko) 2005-05-10
JP2000506543A (ja) 2000-05-30
ZA977327B (en) 1998-03-30
EP0925273B1 (fr) 2001-11-07
CN1227538A (zh) 1999-09-01
CZ49899A3 (cs) 1999-05-12
PL331645A1 (en) 1999-08-02
NO312290B1 (no) 2002-04-22
CZ294165B6 (cs) 2004-10-13
TW438764B (en) 2001-06-07
BR9711315A (pt) 1999-08-17
AR009251A1 (es) 2000-04-12
CN1082370C (zh) 2002-04-10
SK18099A3 (en) 2000-03-13
NO990707L (no) 1999-02-15
SI0925273T1 (en) 2002-04-30
WO1998007681A1 (fr) 1998-02-26
RU2175966C2 (ru) 2001-11-20
CY2298B1 (en) 2003-07-04
KR20000068106A (ko) 2000-11-25
ATE208364T1 (de) 2001-11-15
US6143787A (en) 2000-11-07
AU725440B2 (en) 2000-10-12
TR199900329T2 (xx) 1999-04-21
PL187371B1 (pl) 2004-06-30
EP0925273A1 (fr) 1999-06-30
FR2752422B1 (fr) 1998-11-06

Similar Documents

Publication Publication Date Title
ES2166098T3 (es) Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos.
IE820308L (en) Pharmaceutical composition
ES2185999T3 (es) Derivados de quinazolina y composiciones farmaceuticas que los contienen.
ES2129679T3 (es) Derivados que contienen el grupo amidino, utiles como inhibidores de la sintasa de oxido nitrico.
IL101650A0 (en) Sulphonamides,their manufacture and pharmaceutical compositions containing them
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
GT199700033A (es) Derivados de 6-fenilpiridil-2-amina.
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
ES2102668T3 (es) Composiciones detergentes liquidas que contienen proteasa y ciertos acidos y esteres beta-aminoalquilboronicos.
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
ES2096872T3 (es) Composiciones limpiadoras acuosas acidas.
ES2059786T3 (es) Composicion blanqueante.
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
ES2102994T3 (es) Derivados de benzisotiazolinona-1-dioxido como inhibidores de elastasa.
ES2179332T3 (es) Repelentes de artropodos.
IL47529A (en) Substituted (1-(-4,4-bisphenylbutyl)-4-piperidyl-)1,3-dihydro-2h-benzimidazol-2-one derivatives and certain intermediates for obtaining such compounds,their preparation and pharmaceutical compositions containing them
AR009120A1 (es) Una composicion de grasa de urea y mecanismos que contienen tal composicion
MX9203140A (es) Derivados de 4 fenil-4(n-(fenil)amido)-piperidina y las composiciones farmaceuticas, asi como el metodo aplicado para tales compuestos.
AR005072A1 (es) Derivados del acido 2-(o-(pirimidin-4-il) metilenoxi) fenilacetico, composiciones formuladas con dichos derivados, utilizacion de dichos derivadosy de dichas composiciones para combatir hongos daninos y las alimanas y procedimiento para preparar dichas composiciones y procedimiento de aplicacion
ES2133351T3 (es) Uso de un tioester para preparar composiciones farmaceuticas destinadas al tratamiento de sindromes de isquemia y de reperfusion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 925273

Country of ref document: ES